Adding Zika Virus to the FDA Priority Review Voucher Program Act became law 71 days after introduction, with cosponsors from both parties
Written by the Congressional Research Service [2]. 150 words.
(This measure has not been amended since it was reported to the Senate on March 15, 2016. The summary of that version is repeated here.) Adding Zika Virus to the FDA Priority Review Voucher Program Act
(Sec. 2) This bill amends the Federal Food, Drug, and Cosmetic Act to add Zika virus disease to the list of tropical diseases under the priority review voucher program, which awards a voucher to the sponsor of a new drug or biological product that is approved to prevent or treat a tropical disease. (A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.) The bill makes a technical correction to the tropical disease list to refer to filovirus disease, a condition caused by the family of viruses that includes the Ebola virus, instead of the family of viruses.
- Committees
- House Energy and Commerce Committee
Senate Health, Education, Labor, and Pensions Committee - Policy area
- Health: 122 of 9,357 bills became law, 113th–118th (1.3%)
- Sponsor
- 1 of 99 bills enacted since 2013
- Text versions
- 6, from enrolled bill to public law · 279 words
- Subjects
- Drug safety, medical device, and laboratory regulationDrug therapyInfectious and parasitic diseases
- Latest action
- Apr 19, 2016: Became Public Law No: 114-146.
- Records
- Congress.gov · Bill text
Each bill appears once, under its strongest link. 1 in all.
Identical or companion · 1
- 114th H.R. 4400 Adding Zika Virus to the FDA Priority Review Voucher Program Act D · Introduced